Super-sized golden moon fills York sky - still 2 days to see the spectacle
Almost full, hanging low, and looking super-sized, it shone over the city in a beautiful golden colour.
Lisa Young took these stunning photos of the moon last night and shared them in our Camera Club group on Facebook.
But don't fret if you missed it - the actual full moon will be on Thursday, so you still have a chance to capture its magic.
July's full moon is often referred to as the 'buck moon' - representing the time of year when male deer, known as bucks, begin to grow their new antlers.
For many it marked the start of the game hunting season.
Other nicknames for the July full moon include the Feather Molting Moon and the Salmon Moon.
July's buck moon over York by Lisa Young
It looks large because it lies close to the horizon. It will also be the farthest full moon from the sun all year.
Being so close to the horizon, it may also appear golden or orange, but this will be due to your perspective from earth when observing it, rather than the moon itself, the BBC's Sky at Night Magazine reports.
The Buck Moon, which is the first full moon of summer in the northern hemisphere, will turn full on Thursday, July 10.
The moon is due to rise at around 10pm. Sunset is set to be around 9.30pm on Thursday night, with clear skies predicted for most of the UK as it heads into another heatwave - so there is an excellent chance of seeing the spectacle.
July's buck moon over York by Lisa Young
But that's not all - there's something even more unique about this full moon, as it may be spotted alongside some planets.
Mars will be visible in the evening sky before it sets at around 11.37pm, according to In The Sky.
Saturn won't rise until just after midnight, but you may be able to catch a glimpse of the planet in the morning sky on July 11, before sunrise at around 5am.
Venus, the brightest planet in the night sky, will also make an appearance. It will rise at around 2am in the eastern sky.
For the rest of 2025, the UK will experience full moons on the following dates: August 9, September 7, October 7, November 5, and December 5.
Join our club
WOULD you like to see your photographs in The Press and online?
More than 2,500 readers have joined The Press Camera Club, which launched in June 2017 and brings together talented photographers from across York and North and East Yorkshire to share their work, swap tips and take part in themed monthly prize competitions.
To join the free club, simply search for 'The Press Camera Club' on Facebook - we'd love to see what our region looks like through your lens.
We will feature pictures from our camera club in The Press and online regularly.
If you like seeing photos of York, please follow us on Instagram too @york.press.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Boy with fragile skin disorder given hope after new treatment
A boy with a rare skin condition which can cause damage with even the smallest amount of friction has been given hope after taking part in a trial for the first potential treatment for the genetic disorder. Gabrielius Misurenkovas, 12, from east London, was diagnosed with an inflammatory disease called recessive dystrophic epidermolysis bullosa (RDEB) when he was a baby. Many symptoms of the painful condition have been alleviated thanks to a new trial in which he received certain stem cells via an intravenous drip. The rare genetic disease is severely debilitating. People with the condition have extremely fragile skin which is easily damaged, leading to blistering, deep wounds and scarring. About 150 children in the UK are affected by RDEB, which is painful and causes itchiness. With no disease-modifying treatment available, patients and their families manage symptoms by dressing wounds and applying eye ointments. Over time, the condition can lead to severe complications and many patients with the condition develop a type of skin cancer called squamous cell carcinoma when they are young adults – this is the most common cause of death for RDEB patients. Gabrielius has been under the care of medics at the world-renowned children's hospital Great Ormond Street (GOSH) since he was a baby. He said he jumped at the chance to join the clinical trial when it was suggested by his doctors. 'I wanted to take part in the trial as I was excited to see if it could help improve my condition and so I could do more of the things I enjoy, like playing football and spending time with my friends,' he said. The youngster, who can speak three languages and is a big fan of footballer Lionel Messi, needed his bandages changing three times a day, or more if he was injured. His mother, Jolita Cekaviciene, said: 'Gabrielius did really well on the trial. 'His wounds healed quicker, and his skin was less red and inflamed. 'His skin was also less itchy which also reduced him scratching. 'His sleep was also less disturbed as he didn't need to have his special wound dressings changed as often, so this was a great benefit.' She said Gabrielius has managed to do a few things that he was not able to before the treatment, including taking part in some sports at school, riding his bike in the park on the grass, and being able to play football with his friends, with a soft ball. Ms Cekaviciene said the trial has given her son more freedom than before, but he still needs to be careful in any activity to avoid falling over or bumps. Gabrielius was referred to GOSH as a baby after medics spotted a wound when he was born, and he was diagnosed with RDEB when he was two weeks old. Ms Cekaviciene said: 'The first two years were really hard as you had to watch him constantly – even rubbing his eyes could cause painful blistering. 'He couldn't even tell us how much pain he was in or where he was hurting.' RDEB is a genetic condition which is caused by a fault in the gene that makes a protein which holds layers of skin together – collagen VII. Medics wanted to assess whether regular infusions with mesenchymal stromal cells (MSC) improved symptoms for children with the condition, after studies suggested that MSC treatments could promote wound healing, reduce inflammation and stimulate tissue regeneration. In the trial, funded by NHS England, the National Institute for Health and Care Research and the charity Cure EB, children were given a treatment called CORDStrom, manufactured by INmuneBio. Gabrielius is one of 30 children who took part in the new clinical trial at GOSH and Birmingham Children's Hospital. Patients would go into hospital and have a drip which delivers the cells over 10 to 15 minutes. In the study patients were split into two groups, about half were given the treatment, which is made from umbilical cord tissue, as an infusion, twice over two weeks. The other half were given a placebo, also known as a dummy drug. They then had a nine-month gap, known as a wash-out period, where the group that were initially given the dummy drug were given the treatment, while the group that received therapy first were given a dummy drug. The study, published in the journal eClinicalMedicine, reported a positive outcome of the treatment. The largest effects were in children under the age of 10, and in the children with intermediate type of RDEB. Families involved in the study reported a positive impact on daily life and well-being, with a reduction in both pain and itching. The treatment was said to be well tolerated by the children. INmuneBio have agreed to provide CORDStrom free of charge for a year for all children who took part in the trial, so researchers can continue to study them, and patients are expected to get two infusions of the treatment every four months. The company is seeking regulatory approval for the treatment so it can be approved for use in the UK and other countries. Chief investigator of the study, Dr Anna Martinez, paediatric dermatologist at GOSH, said: 'Our study has demonstrated that CORDStrom was safe and can help reduce disease activity in some patients with RDEB. 'Administering the treatment early and at regular intervals appears to reduce itch and improve wound healing, which over time we hope will reduce inflammation, modify the condition and may reduce over time the future risk of squamous cell carcinoma. 'It's fantastic to see how the patients, like Gabrielius, had improvements in their symptoms and their quality of life.' She added: 'The 12-month open label study will allow us to collect more data to hopefully show an increased benefit from treatments administered in children and young people with RDEB, to continue research in support of the treatment being rolled out more widely.' Sharmila Collins, founder trustee of Cure EB, said: 'Since funding the first trial and by contributing to Mission EB we have been working towards bringing MSC infusions forward for all children in the UK with RDEB. 'We hope these cells will become part of routine clinical care to alleviate the significant suffering of children with this condition.'
New York Times
7 hours ago
- New York Times
Margaret Boden, Philosopher of Artificial Intelligence, Dies at 88
Margaret Boden, a British philosopher and cognitive scientist who used the language of computers to explore the nature of thought and creativity, leading her to prescient insights about the possibilities and limitations of artificial intelligence, died on July 18 in Brighton, England. She was 88. Her death, in a care home, was announced by the University of Sussex, where in the early 1970s she helped establish what is now known as the Center for Cognitive Science, bringing together psychologists, linguists, neuroscientists and philosophers to collaborate on studying the mind. Polymathic, erudite and a trailblazer in a field dominated by men, Professor Boden produced a number of books — most notably 'The Creative Mind: Myths and Mechanisms' (1990) and 'Mind as Machine: A History of Cognitive Science' (2006) — that helped shape the philosophical conversation about human and artificial intelligence for decades. 'What's unique about Maggie is that she's a philosopher who has informed, inspired and shaped science,' Blay Whitby, a philosopher and ethicist, said on the BBC radio show 'The Life Scientific' in 2014. 'It's important I emphasize that, because many modern scientists say that philosophers have got nothing to tell them, and they'd be advised to look at the work and life of Maggie Boden.' Professor Boden was not adept at using computers. 'I can't cope with the damn things,' she once said. 'I have a Mac on my desk, and if anything goes wrong, it's an absolute nightmare.' Nevertheless, she viewed computing as a way to help explain the mechanisms of human thought. To her, creativity wasn't divine or a result of eureka-like magic, but rather a process that could be modeled and even simulated by computers. Want all of The Times? Subscribe.
Medscape
9 hours ago
- Medscape
Cycling and Education for Hip OA: A Cost-Effective Solution?
TOPLINE: A cycling and education intervention significantly improved self-reported function in hip osteoarthritis (OA) compared with standard physiotherapy. The group-based intervention was also cost-effective, with a cost per quality-adjusted life year below the National Institute for Health and Care Excellence (NICE) threshold. METHODOLOGY: Researchers conducted a pragmatic randomized controlled trial comparing a group-based cycling and education intervention with usual physiotherapy care for hip OA (the CLEAT trial) in Bournemouth, UK. A total of 221 patients (mean age, 64.4 years; 57% women; 98% White) with hip OA, as defined by NICE criteria, who met the primary care criteria for exercise referral were randomly assigned to either cycling against hip pain intervention (CHAIN, 110 participants) or usual physiotherapy care (111 participants). Participants in the cycling group attended an 8-week program comprising education and static cycling sessions at a local leisure center, facilitated by a physiotherapist and a gym instructor, respectively. The physiotherapy group received usual one-to-one care, including exercise, education, and other physiotherapy techniques, at the local hospital or by telephone. The primary outcome was the between-group difference in the self-reported function of performing everyday activities, measured using the Hip Disability and Osteoarthritis Outcome Score (HOOS) activities of daily living subscale at 10 weeks post-treatment. The analysis included a parallel economic evaluation from the perspective of the UK National Health Service (NHS) and personal social services, assessing cost per quality-adjusted life year at 3 months after treatment. TAKEAWAY: Patients in the cycling group showed a significant improvement in the HOOS activities of daily living score at 10 weeks post-treatment compared with those in the physiotherapy group (adjusted mean difference, 6.9; P = .0023). The cycling group experienced improvements in secondary outcomes, with significant increases in scores for symptoms and stiffness (P = .0072), sports (P = .022), and quality of life (P = .042), but no improvement in pain score. No significant differences were observed in physiologic measures such as BMI, blood pressure, or resting heart rate between the cycling and physiotherapy groups. The CHAIN intervention was cost-effective, with a base case analysis cost per quality-adjusted life year of £4092, and showed a high probability of cost-effectiveness at NICE thresholds compared with physiotherapy. IN PRACTICE: "Taken together, these findings add to a growing body of evidence suggesting that, although exercise is beneficial, between-group differences in function and pain are often small when comparing active interventions," the authors of the study wrote. "Although the study did not identify a clinically meaningful between-group difference, CHAIN's cost-effectiveness within the NHS positions it as a viable alternative to usual physiotherapy care," they added. "From the patient's perspective, cycling combined with patient education offers a simple and accessible treatment approach," experts wrote in an accompanying comment. "From the perspective of decision makers, the group-based nature of CHAIN presents a highly cost-effective option for implementation in first-line treatment. Given that a single healthcare provider can deliver this intervention to many patients at a time, CHAIN provides scalability and resource efficiency, which are essential in publicly funded healthcare systems." SOURCE: The study was led by Thomas W. Wainwright, PhD, University Hospitals Dorset NHS Foundation Trust in Bournemouth, UK. It was published online on July 31, 2025, in The Lancet Rheumatology. LIMITATIONS: Most participants did not have radiographic confirmation of OA, affecting baseline severity assessment. The inability to mask participants and treatment providers introduces a risk of performance bias, potentially influencing self-reported outcomes. The exclusion of individuals unable to complete the exercise tolerance test limits applicability to those with lower fitness levels. DISCLOSURES: The study was supported by the Research for Patient Benefit Programme of the National Institute for Health and Care Research. One author disclosed receiving institutional research funding and personal fees, while another author reported receiving royalties and consulting fees from various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
